论文部分内容阅读
目的观察可必特与沐舒坦联合雾化吸入对慢性阻塞性肺疾病急性加重期患者的临床疗效。方法将98例慢性阻塞性肺疾病急性加重期的住院患者随机分为2组,除常规给予抗生素、氨茶碱、甲强龙等治疗外,对照组49例给予沐舒坦15mg,每日2次雾化吸入,治疗组49例给予沐舒坦15mg,可必特2.5ml联合每日2次雾化吸入。结果两组患者用药7d后症状、体征改善的有效率差异有统计学意义(P<0.05);两组氧分压、二氧化碳分压比较差异有统计学意义(P<0.05);治疗后肺功能指标(FEV1,FEV1/FVC%)两组比较差异均有统计学意义(P<0.05)。结论可必特和沐舒坦联合雾化吸入能改善慢性阻塞性肺疾病急性加重期患者的肺功能、临床症状及缓解低氧和二氧化碳潴留。
Objective To observe the clinical efficacy of combiblocin inhalation combined with ambroxol on patients with acute exacerbation of chronic obstructive pulmonary disease. Methods A total of 98 patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) were randomly divided into two groups. Except for routine antibiotics, aminophylline and methylprednisolone, 49 patients in the control group were given ambroxol 15 mg twice daily Inhalation inhalation, the treatment group of 49 patients given mucosolvan 15mg, may be special 2.5ml combined with 2 times daily inhalation. Results The effective rate of symptom and symptom improvement was significantly different between the two groups after 7 days (P <0.05). There was significant difference between the two groups in the partial pressure of oxygen and the partial pressure of carbon dioxide (P <0.05). The pulmonary function The indexes (FEV1, FEV1 / FVC%) were significantly different between the two groups (P <0.05). Conclusions Combination of canine and mucosolvan can improve lung function, clinical symptoms and relieve hypoxia and carbon dioxide retention in patients with acute exacerbation of chronic obstructive pulmonary disease.